OrSense Ltd., a Nes Ziona, Israel company, is reporting that its NBM-200G non-invasive continuous monitor of blood glucose for diabetics has been granted the CE Mark of approval in the EU. The bulky device is illustrated below, and the picture above shows expected appearance of the next generation device based on the company’s proprietary technology.
The NBM-200G is based on OrSense’s proprietary breakthrough technology that allows non-invasive measurement of analytes including glucose, hemoglobin, and oxygen saturation with very high sensitivity. The NBM-200G is operated by placing a ring-shaped probe around the patient’s finger, which applies a gentle pressure to the finger, similar to that applied during non-invasive blood-pressure measurement and temporarily occludes the blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the patient’s blood glucose. The method was tested on over 400 subjects, exhibiting comparable accuracy to invasive solutions, while providing superior ease of use and safety. In addition, the NBM-200G enables the identification of glucose trends and the detection of hypo- and hyperglycemia events and may also optimally answer the growing need for tight glycemic control in acute care settings, thereby reducing morbidity and mortality.